Follow

DBP International AB: participate in semi-final of EIT Health Catapult 2020

16 October 2020 - 15:57

Double Bond Pharmaceutical International AB (publ) (“Double Bond Pharmaceutical” eller “DBP”) was selected to pitch in the EIT Health Catapult semifinals in the biotech sector. The CEO Igor Lokot will present the company on Wednesday, October 21 at 10:45.

Register for free to attend this year’s virtual pitch:

 https://www.europeanhealthcatapult.eu/register-for-semifinals.

“Double Bond Pharmaceutical provides unique investment opportunity: our ambitious team made a huge work in the development of SI-053 as a game-changer for treatment of malignancies in the brain; now I need to explain the potential to the investment community and EIT Health Catapult 2020 is a very good opportunity for that”, - comments Igor Lokot, CEO of Double Bond Pharmaceutical. 

More about EIT Health Catapult 2020: EIT Health Catapult is a leading program sourcing and accelerating the best healthcare start-ups in Europe.

Contact info DBP:

Igor Lokot, CEO

igor@doublebp.com

Provided by: Cision
Spotlight (Sweden)
Double Bond Pharmaceutical International AB
Double Bond Pharmaceutical International AB is a pharmaceutical company specializing in the treatment of cancer diseases through a proprietary drug delivery technology BeloGal ™. With the help of this technology, the company wants to set a new standard for drug administration in the treatment of oncological, infectious, autoimmune and other diseases....
Learn more about company
Media

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date